Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target

被引:8
作者
Gill, Dipender
Tan, Peng H. [1 ,2 ]
机构
[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford Radcliffe Hosp NHS Trust, Oxford OX3 9DU, England
[2] John Radcliffe Hosp, Oxford Radcliffe Hosp NHS Trust, Oxford Breast Unit, Oxford OX3 9DU, England
关键词
autoimmunity; clinical transplantation; cytotoxic T lymphocytes; dendritic cells; NF-KAPPA-B; CARDIAC ALLOGRAFT SURVIVAL; COLLAGEN-INDUCED ARTHRITIS; ACQUIRED THYMIC TOLERANCE; LONG-TERM SURVIVAL; IN-VIVO; FAS-LIGAND; ANTIGEN PRESENTATION; ACTIVATION GENE-3; APOPTOTIC CELLS;
D O I
10.1517/14728222.2010.499360
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Dendritic cells (DCs) have an important role, both direct and indirect, in controlling the expansion and function of T cells. Of the different subsets of T cells, cytotoxic T lymphocytes (CTLs/CD8(+) T cells) have been implicated in the pathogenesis and development of many diseases, including various forms of autoimmunity and transplant rejection. It may therefore be of therapeutic benefit to control the function of CTL in order to modulate disease processes and to ameliorate disease symptoms. Currently, pharmacological approaches have been employed to either directly or indirectly modulate the function of T cells. However, these treatment strategies have many limitations. Many experimental data have suggested that it is possible to alter CTL activity through manipulation of DC. Areas covered in this review: Novel strategies that condition DCs to influence disease outcome through manipulation of CTL activity, both directly and indirectly. This includes the modulation of co-stimulation, negative co-stimulation, as well as manipulation of the cytokine milieu during CTL generation. Furthermore, DCs may also impact CTL activity through effects on effector and regulatory cells, along with manipulation of bioenergetic regulation, apoptotic-cell mediated tolerance and through the generation of exosomes. The implications of related interventions in the clinical arena are in turn considered. What the reader will gain: Insight into such indirect methods of controlling CTL activity allows for an understanding of how disease-specific T cells may be regulated, while also sparing other aspects of adaptive immunity for normal physiological function. Such an approach towards the treatment of disease represents an innovative therapeutic target in the clinical arena. Take home message: There are numerous innovative methods for using DCs to control CTL responses. Manipulation of this interaction is thus an attractive avenue for the treatment of disease, particularly those of immune dysregulation, such as seen in autoimmunity and transplantation. With the number of studies moving into clinical stages constantly increasing, further advances and successes in this area are inevitable.
引用
收藏
页码:797 / 824
页数:28
相关论文
共 280 条
  • [1] Interferon-γ-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis
    Adikari, SB
    Lian, H
    Link, H
    Huang, YM
    Xiao, BG
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 138 (02) : 230 - 236
  • [2] DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties
    Aiello, Sistiana
    Cassis, Paola
    Cassis, Linda
    Tomasoni, Susanna
    Benigni, Ariela
    Pezzotta, Anna
    Cavinato, Regiane A.
    Cugini, Daniela
    Azzollini, Nadia
    Mister, Marilena
    Longaretti, Lorena
    Thomson, Angus W.
    Remuzzi, Giuseppe
    Noris, Marina
    [J]. TRANSPLANTATION, 2007, 83 (04) : 474 - 484
  • [3] Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
    Albert, ML
    Pearce, SFA
    Francisco, LM
    Sauter, B
    Roy, P
    Silverstein, RL
    Bhardwaj, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (07) : 1359 - 1368
  • [4] Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells
    Ali, A
    Garrovillo, M
    Jin, MX
    Hardy, MA
    Oluwole, SF
    [J]. TRANSPLANTATION, 2000, 69 (02) : 221 - 226
  • [5] Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming
    Allan, Rhys S.
    Waithman, Jason
    Bedoui, Sammy
    Jones, Claerwen M.
    Villadangos, Jose A.
    Zhan, Yifan
    Lew, Andrew M.
    Shortman, Ken
    Heath, William R.
    Carbone, Francis R.
    [J]. IMMUNITY, 2006, 25 (01) : 153 - 162
  • [6] Expansion of the antigenic repertoire of a single T cell receptor upon T cell activation
    Amrani, A
    Serra, P
    Yamanouchi, J
    Trudeau, JD
    Tan, RS
    Elliott, JF
    Santamaria, P
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (02) : 655 - 666
  • [7] Perforin-independent β-cell destruction by diabetogenic CD8+ T lymphocytes in transgenic nonobese diabetic mice
    Amrani, A
    Verdaguer, J
    Anderson, B
    Utsugi, T
    Bou, S
    Santamaria, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (08) : 1201 - 1209
  • [8] Prevalent CD8+ T cell response against one peptide/MHC complex in autoimmune diabetes
    Anderson, B
    Park, BJ
    Verdaguer, J
    Amrani, A
    Santamaria, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (16) : 9311 - 9316
  • [9] Exosomes as potent cell-free peptide-based vaccine.: I.: Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells
    André, F
    Chaput, N
    Schartz, NEC
    Flament, C
    Aubert, N
    Bernard, J
    Lemonnier, F
    Raposo, G
    Escudier, B
    Hsu, DH
    Tursz, T
    Amigorena, S
    Angevin, E
    Zitvogel, L
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04) : 2126 - 2136
  • [10] Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)
    Andreae, S
    Piras, F
    Burdin, N
    Triebel, F
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (08) : 3874 - 3880